CUL3 monoubiquitylates NOLC1 together with TCOF1, thereby remodeling the translational program of differentiating cells in favor of neural crest specification and determining cell fate.28 It can also activate alpha-1-acid glycoprotein in mammalian livers as a transcriptional regulator.29 In addition, human NOLC1 is a binding target of doxorubicin, a widely used anti-cancer drug,30 and can also bind to and inhibit the catalytic subunit of CK2 in vitro. Here, NOLC1 is linked to cancer.